Interleukin-6  	Interleukin-6  	 FW	B-NP
attenuates  	attenuates  	 FW	O
serotonin  	serotonin  	 FW	O
2a  	2a  	 FW	O
receptor  	receptor  	 FW	O
signaling  	signaling  	 FW	O
by  	by  	 IN	O
activating  	activating  	 VBG	O
the  	the  	 DT	O
JAK-STAT  	JAK-STAT  	 JJ	B-NP
pathway  	pathway  	 NNS	I-NP
The  	The  	 DT	O
serotonin  	serotonin  	 JJ	O
2A  	2A  	 NNP	O
( 	( 	 -LRB-	O
5-HT2A 	5-HT2A 	 NNP	O
)  	)  	 -RRB-	O
receptor  	receptor  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
proinflammatory  	proinflammatory  	 JJ	B-NP
cytokine 	cytokine 	 NN	I-NP
,  	,  	 ,	O
interleukin-6  	interleukin-6  	 NNP	B-NP
( 	( 	 -LRB-	O
IL-6 	IL-6 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
have  	have  	 VBP	O
both  	both  	 DT	O
been  	been  	 VBN	O
implicated  	implicated  	 VBN	O
in  	in  	 IN	O
psychiatric  	psychiatric  	 JJ	B-NP
disorders 	disorders 	 NNS	I-NP
.  	.  	 .	O
Previously 	Previously 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
demonstrated  	demonstrated  	 VBD	O
that  	that  	 IN	O
these  	these  	 DT	O
molecules  	molecules  	 NNS	O
both  	both  	 CC	O
facilitate  	facilitate  	 VB	O
cognitive  	cognitive  	 JJ	B-NP
flexibility 	flexibility 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
prefrontal  	prefrontal  	 JJ	B-NP
cortex-mediated  	cortex-mediated  	 JJ	I-NP
executive  	executive  	 NN	I-NP
function  	function  	 VBP	O
impaired  	impaired  	 VBN	O
in  	in  	 IN	O
multiple  	multiple  	 JJ	O
mental  	mental  	 JJ	B-NP
illnesses 	illnesses 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
study 	study 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
tested  	tested  	 VBD	O
the  	the  	 DT	O
hypothesis  	hypothesis  	 NN	O
that  	that  	 IN	O
IL-6  	IL-6  	 FW	B-NP
influences  	influences  	 FW	I-NP
5-HT2A  	5-HT2A  	 FW	O
receptor  	receptor  	 FW	O
signaling 	signaling 	 FW	O
,  	,  	 ,	O
providing  	providing  	 VBG	O
a  	a  	 DT	O
potential  	potential  	 JJ	B-NP
mechanism  	mechanism  	 NN	I-NP
by  	by  	 IN	O
which  	which  	 WDT	O
this  	this  	 DT	O
cytokine  	cytokine  	 NN	B-NP
may  	may  	 MD	O
influence  	influence  	 VB	O
behavior 	behavior 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
first  	first  	 RB	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
5-HT2A  	5-HT2A  	 CD	O
receptors  	receptors  	 NNS	O
and  	and  	 CC	O
IL-6-mediated  	IL-6-mediated  	 CD	B-NP
STAT3  	STAT3  	 CD	I-NP
phosphorylation  	phosphorylation  	 JJ	I-NP
colocalize  	colocalize  	 NN	I-NP
in  	in  	 IN	O
cells  	cells  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
prefrontal  	prefrontal  	 JJ	B-NP
cortex 	cortex 	 NN	I-NP
,  	,  	 ,	O
providing  	providing  	 VBG	O
the  	the  	 DT	O
neuroanatomical  	neuroanatomical  	 JJ	B-NP
substrate  	substrate  	 NN	I-NP
for  	for  	 IN	I-NP
a  	a  	 DT	I-NP
potential  	potential  	 JJ	I-NP
interaction 	interaction 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
neuronally  	neuronally  	 NN	O
derived  	derived  	 VBD	O
A1A1  	A1A1  	 CD	O
cell  	cell  	 NN	O
line 	line 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
expresses  	expresses  	 VBZ	O
both  	both  	 DT	O
IL-6  	IL-6  	 NNP	B-NP
and  	and  	 CC	O
5-HT2A  	5-HT2A  	 CD	O
receptors 	receptors 	 NNS	O
,  	,  	 ,	O
we  	we  	 PRP	O
found  	found  	 VBD	O
that  	that  	 IN	O
IL-6  	IL-6  	 FW	B-NP
attenuates  	attenuates  	 FW	O
inositol  	inositol  	 FW	B-NP
phosphate  	phosphate  	 FW	I-NP
( 	( 	 -LRB-	O
IP 	IP 	 NNP	B-NP
)  	)  	 -RRB-	O
accumulation  	accumulation  	 NN	B-NP
in  	in  	 IN	O
response  	response  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
5-HT2  	5-HT2  	 JJ	B-NP
agonist 	agonist 	 NN	I-NP
,  	,  	 ,	O
2,5-dimethoxy-4-iodoamphetamine  	2,5-dimethoxy-4-iodoamphetamine  	 NNP	O
( 	( 	 -LRB-	O
DOI 	DOI 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
suggesting  	suggesting  	 VBG	O
that  	that  	 IN	O
IL-6  	IL-6  	 NNP	B-NP
can  	can  	 MD	O
regulate  	regulate  	 VB	O
5-HT2A  	5-HT2A  	 CD	O
receptor  	receptor  	 NN	O
function 	function 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
identify  	identify  	 VB	O
the  	the  	 DT	O
signaling  	signaling  	 JJ	O
pathway 	pathway 	 NNS	B-NP
( 	( 	 -LRB-	I-NP
s 	s 	 LS	I-NP
)  	)  	 -RRB-	I-NP
that  	that  	 WDT	O
mediate  	mediate  	 VBZ	O
this  	this  	 DT	O
effect 	effect 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
measured  	measured  	 VBD	B-NP
DOI-mediated  	DOI-mediated  	 NNP	I-NP
IP  	IP  	 NNP	I-NP
accumulation  	accumulation  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
IL-6  	IL-6  	 NNP	B-NP
and  	and  	 CC	O
either  	either  	 RB	O
the  	the  	 DT	O
JAK-STAT  	JAK-STAT  	 JJ	B-NP
inhibitor  	inhibitor  	 NN	I-NP
124  	124  	 CD	O
[ 	[ 	 CD	O
( 	( 	 -LRB-	O
9β 	9β 	 NNP	O
, 	, 	 ,	O
10α 	10α 	 NNP	O
, 	, 	 ,	O
16α 	16α 	 NNP	O
, 	, 	 ,	O
23E 	23E 	 CD	O
) 	) 	 -RRB-	O
-2,16,20,25-tetrahydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione 	-2,16,20,25-tetrahydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione 	 CD	O
] 	] 	 -RRB-	O
,  	,  	 ,	O
JSI-124 	JSI-124 	 NNP	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
the  	the  	 DT	O
extracellular  	extracellular  	 JJ	B-NP
signal-regulated  	signal-regulated  	 JJ	I-NP
kinase  	kinase  	 JJ	I-NP
inhibitor 	inhibitor 	 NN	I-NP
,  	,  	 ,	O
2- 	2- 	 NNP	O
( 	( 	 -LRB-	O
2-amino-3-methoxyphenyl 	2-amino-3-methoxyphenyl 	 NNP	O
) 	) 	 -RRB-	O
-4H-1-benzopyran-4-one  	-4H-1-benzopyran-4-one  	 NNP	O
( 	( 	 -LRB-	O
PD-98059 	PD-98059 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
IL-6  	IL-6  	 JJ	B-NP
effect  	effect  	 NN	I-NP
was  	was  	 VBD	O
blocked  	blocked  	 VBN	O
by  	by  	 IN	O
JSI-124  	JSI-124  	 NNP	B-NP
but  	but  	 CC	O
not  	not  	 RB	O
PD-98059 	PD-98059 	 CD	B-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
silencing  	silencing  	 VBG	B-NP
RNA  	RNA  	 NNP	I-NP
knockdown  	knockdown  	 NN	O
of  	of  	 IN	O
either  	either  	 DT	O
JAK  	JAK  	 NNP	B-NP
or  	or  	 CC	O
STAT  	STAT  	 NNP	B-NP
blocked  	blocked  	 VBD	O
the  	the  	 DT	O
IL-6  	IL-6  	 JJ	B-NP
effect 	effect 	 NN	I-NP
,  	,  	 ,	O
suggesting  	suggesting  	 VBG	O
that  	that  	 IN	O
IL-6-induced  	IL-6-induced  	 CD	B-NP
JAK-STAT  	JAK-STAT  	 JJ	I-NP
activation  	activation  	 NN	I-NP
can  	can  	 MD	O
regulate  	regulate  	 VB	O
5-HT2A  	5-HT2A  	 CD	O
receptor  	receptor  	 NN	O
signaling 	signaling 	 NN	O
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
to  	to  	 TO	O
determine  	determine  	 VB	O
if  	if  	 IN	O
IL-6  	IL-6  	 NNP	B-NP
specifically  	specifically  	 RB	O
regulates  	regulates  	 VBZ	O
the  	the  	 DT	O
5-HT2A  	5-HT2A  	 JJ	O
receptor  	receptor  	 NN	O
system 	system 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
measured  	measured  	 VBD	B-NP
IP  	IP  	 NNP	I-NP
production  	production  	 NN	I-NP
mediated  	mediated  	 NN	I-NP
by  	by  	 IN	O
another  	another  	 DT	O
Gq-coupled  	Gq-coupled  	 JJ	B-NP
receptor 	receptor 	 NN	I-NP
,  	,  	 ,	O
bradykinin  	bradykinin  	 JJ	B-NP
B2 	B2 	 NN	I-NP
.  	.  	 .	O
IL-6  	IL-6  	 NNP	B-NP
had  	had  	 VBD	O
no  	no  	 DT	O
effect  	effect  	 NN	O
on  	on  	 IN	O
bradykinin-mediated  	bradykinin-mediated  	 NNP	B-NP
IP  	IP  	 NNP	I-NP
accumulation 	accumulation 	 NN	I-NP
,  	,  	 ,	O
suggesting  	suggesting  	 VBG	O
that  	that  	 DT	O
regulation  	regulation  	 NN	O
may  	may  	 MD	O
occur  	occur  	 VB	O
at  	at  	 IN	O
the  	the  	 DT	O
5-HT2A  	5-HT2A  	 JJ	O
receptor 	receptor 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
results  	results  	 NNS	O
may  	may  	 MD	O
provide  	provide  	 VB	O
clues  	clues  	 NNS	O
to  	to  	 TO	O
the  	the  	 DT	O
pathologic  	pathologic  	 JJ	B-NP
mechanisms  	mechanisms  	 NNS	I-NP
underlying  	underlying  	 VBG	O
certain  	certain  	 JJ	O
psychiatric  	psychiatric  	 JJ	B-NP
disorders  	disorders  	 NNS	I-NP
and  	and  	 CC	O
may  	may  	 MD	O
suggest  	suggest  	 VB	O
novel  	novel  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
for  	for  	 IN	O
their  	their  	 PRP$	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
